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OBJECTIVE—Interleukin-21 (IL-21) is a proinﬂammatory cyto-
kine that has been shown to affect Treg/Teff balance. However,
the mechanism by which IL-21 orchestrates alloimmune response
and interplays with Tregs is still unclear.
RESEARCH DESIGN AND METHODS—The interplay be-
tween IL-21/IL-21R signaling, FoxP3 expression, and Treg sur-
vival and function was evaluated in vitro in immunologically
relevant assays and in vivo in allogenic and autoimmune models
of islet transplantation.
RESULTS—IL-21R expression decreases on T cells and B cells
in vitro and increases in the graft in vivo, while IL-21 levels in-
crease in vitro and in vivo during anti-CD3/anti-CD28 stimulation/
allostimulation in the late phase of the alloimmune response.
In vitro, IL-21/IL-21R signaling (by using rmIL-21 or genetically
modiﬁed CD4
+ T cells [IL-21 pOrf plasmid–treated or hIL-21-Tg
mice]) enhances the T-cell response during anti-CD3/anti-CD28
stimulation/allostimulation, prevents Treg generation, inhibits
Treg function, induces Treg apoptosis, and reduces FoxP3 and
FoxP3-dependent gene transcripts without affecting FoxP3 meth-
ylation status. In vivo targeting of IL-21/IL-21R expands intragraft
and peripheral Tregs, promotes Treg neogenesis, and regulates
the antidonor immune response, whereas IL-21/IL-21R signaling
in Doxa-inducible ROSA-rtTA-IL-21-Tg mice expands Teffs and
FoxP3
2 cells. Treatment with a combination of mIL-21R.Fc and
CTLA4-Ig (an inhibitor of the early alloimmune response) leads to
robust graft tolerance in a purely alloimmune setting and pro-
longed islet graft survival in NOD mice.
CONCLUSIONS—IL-21 interferes with different checkpoints of
the FoxP3 Treg chain in the late phase of alloimmune response
and, thus, acts as an antitolerogenic cytokine. Blockade of the
IL-21/IL-21R pathway could be a precondition for tolerogenic
protocols in transplantation. Diabetes 60:3223–3234, 2011
T
he alloimmune response is a complex phenom-
enon, based on the activation of the innate and
adaptive immune responses, which invariably
leads to allograft rejection (1). Autocrine soluble
factors, such as cytokines, are able to enhance or alter-
natively suppress the alloimmune response (1). While in-
terleukin (IL)-2 and g-interferon (IFN-g) are among the
primary mediators of the early phase of the alloimmune
response (2), little is known regarding the late phase of the
alloimmune response, during which alloreactive T cells are
recruited to the proliferating pool, thus continuing the
expansion process, while regulatory T cells (Tregs) are
inhibited in exerting their suppressive function (3).
IL-21 is a cytokine produced by activated CD4
+ T cells and
NK cells that has been demonstrated to directly contribute
to the orchestration of the different pathways that regulate
the immune response (4,5). IL-21 binds the IL-21 receptor
(IL-21R) heterodimer and provides signals to CD8
+ naïve T
cells to differentiate into cytotoxic effector cells (6) and
signals to CD4
+ T cells to differentiate into Th17 cells (7–9).
It was recently demonstrated that IL-21 has a role in graft-
versus-host disease (10,11). The basis of considering IL-21 as
an important player in the alloimmune response lies in 1)i t s
robust role in expanding effector T cells (Teffs) (6,12) and 2)
its potential inhibitory role on Tregs (8,9). First, IL-21 has
been shown to have a role in driving the expansion of Teffs
in different disease models (8,13); second, IL-21 has been
previously shown to inhibit transforming growth factor
(TGF)-b–driven differentiation of naïve T cells into Tregs
(8,9), thereby enhancing cytotoxic T-cell generation (14).
Tregs control the immune response, and an IL-21–mediated
impairment of Treg numbers or function may ultimately re-
sult in the impossibility of tolerance induction (15–17). Few
data are available thus far on the interplay of IL-21 and Tregs
in the alloimmune response (10,11,18).
Our aim is to study how the IL-21/IL-21R pathway interacts
with FoxP3 and Tregs during alloimmune response and to
explore whether IL-21 may act as an antitolerogenic cyto-
kine, thus representing a barrier to tolerance.
RESEARCH DESIGN AND METHODS
Mice. The following mice were used: C57BL/6, DBA/1J, BALB/c, Rag1
tm1Mom,
B6-FoxP3-GFP knock-in, IL-21R
2/2, and hIL-21-Tg (15), all in a C57BL/6
background.
Doxycycline-inducible ROSA-rtTA-IL-21-Tg mice. Transgenic C57BL/6
mice expressing mIL-21 cDNA under the control of a tetracycline-dependent
promoter were crossed to ROSA-rtTA mice (see Supplementary Data). Mice
were administered streptozotocin (STZ), transplanted with BALB/c islets, and
treated the same day with doxycycline (2 mg/mL in drinking water until
rejection).
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ORIGINAL ARTICLEImmunological assays. Anti-CD3/anti-CD28 (anti-CD3/CD28) stimulation as-
say and mixed-lymphocyte reaction (MLR) assay were performed as described
previously (19). In vitro assays to study generation, survival, and function of
CD4
+CD25
+ Tregs were performed as previously described (17,20,21).
Protocol. Islet-transplanted mice were treated with 400 mg mIL-21R.Fc (.99%
purity; Pﬁzer, Cambridge, MA) or with 400 mg i.p. of a negative-control IgG2a
antibody (anti–Eimeria tenella) every day for 10 days and then three times per
week for a total of 4 weeks (22). A group of mice was treated with mIL-21R.Fc
in combination with CTLA4-Ig (Abatacept, Orencia; Bristol-Myers Squibb,
Princeton, NJ) (500 mg at day 0 and 250 mg at days 2, 4, 6, 8, and 10).
Statistical analyses. Data are expressed as mean 6 standard error. Kaplan-
Meier analysis (log-rank test) was performed for survival studies. A P value of
,0.05 (by two-tailed testing) was considered an indicator of statistical sig-
niﬁcance. Analyses of data were performed using an SPSS statistical package
for Windows (SPSS Inc., Chicago, IL).
RESULTS
IL-21/IL-21R levels and expression after anti-CD3/
CD28 stimulation and allostimulation in vitro. IL-21R
is highly expressed on naïve unstimulated CD4
+, CD8
+,
and B220
+ cells at baseline, and in contrast with previ-
ously published data (23), the percentage of IL-21R
+ cells
is unchanged on stimulated cells at day 1 and at day 3 (Fig.
1A and B) (some data not shown). It is interesting that
after 5 days of anti-CD3/CD28 stimulation, a reduction in
the percentage of IL-21R
+ T cells and B cells was evident
compared with baseline (IL-21R
+CD4
+ T cells = 8.5 6 1.7%;
IL-21R
+CD8
+ T cells = 14.9 6 5.6%; IL-21R
+B220
+ cells =
21.5 6 14.5%; baseline vs. all, P , 0.05) (Fig. 1C and D). IL-21
was undetectable in the supernatant at day 1 (Fig. 1E) and
at day 3 (data not shown). However, increased levels of
IL-21 in the supernatant were found at day 5 compared
with day 1 (P , 0.001) in the anti-CD3/CD28 stimulation
assay (Fig. 1E and F). When 150 ng/mL of recombinant
mouse (rm)IL-21 was added in vitro, IL-21 supernatant
levels were higher at day 1 compared with day 5 (P ,
0.001) (Fig. 1E and F), possibly for rmIL-21 degradation.
At day 5 (but not at days 1 or 3), an overall reduction in
the percentage of IL-21R
+CD4
+/CD8
+/B220
+ cells was evi-
dent (Fig. 1A–D) (some data not shown) regardless of the
presence of rmIL-21 or mIL-21R.Fc. The addition of mIL-
21R.Fc reduced IL-21 levels in the supernatant at day 5,
when IL-21 ﬁrst became detectable (Fig. 1F). Data ob-
tained from anti-CD3/CD28 stimulation assay data were
conﬁrmed in the MLR assay as well (data not shown). To
conﬁrm that mIL-21R.Fc binds IL-21 cytokine (thus re-
ducing IL-21 detectable levels in vitro), we added serial
concentrations of mIL-21R.Fc (5, 50, and 150 ng/mL) to 150
ng/mL of rmIL-21 and evaluated IL-21 levels by Luminex
assay (Millipore, Billerica, MA) at days 1, 3, and 5 after
seeding. Reduced IL-21 levels were detected when rmIL-21
and mIL-21R.Fc were cocultured (i.e., IL-21 levels at day 1:
no drug = 3290 6 337 vs. mIL-21R.Fc 150 ng/mL = 1135 6
284; P , 0.05).
IL-21/IL-21R signaling enhances the T-cell response
during anti-CD3/CD28 stimulation and allostimulation
in vitro. We ﬁrst challenged CD4
+ and CD8
+ T cells ex-
tracted from the spleens of 10-week-old C57BL/6 mice in
an anti-CD3/CD28 stimulation assay with the addition of
rmIL-21 or mIL-21R.Fc. Addition of rmIL-21 led to a dose-
dependent increase of IFN-g–producing CD4
+ T cells (no
drug = 70.5 6 6.5; 5 ng/mL rmIL-21 = 91.7 6 15.9; 50 ng/mL
rmIL-21 = 104.8 6 7.7; 150 ng/mL rmIL-21 = 110.8 6 8.3,
counted as number of IFN-g–producing cells per 0.2 3
10
6 total CD4
+ T cells; no drug vs. 50 ng/mL rmIL-21 and
150 ng/mL rmIL-21, P , 0.01) (Fig. 1G) and CD8
+ Tc e l l s
(Fig. 1H). IL-4–producing CD4
+ T cells increased in frequency
as well when rmIL-21 was added to the anti-CD3/CD28 as-
say, while no IL-4–producing CD8
+ T cells were detected in
this assay (data not shown). These data were conﬁrmed in
an allostimulation assay (MLR) (data not shown). Addition
of mIL-21R.Fc to the anti-CD3/CD28 assay induced a de-
crease in IFN-g levels and left IL-4 unchanged (Fig. 1I),
while rmIL-21 increased IFN-g and IL-4 levels (Fig. 1J)5
days after stimulation.
We then evaluated the effect of genetically over-
expressing or knocking down the IL-21/IL-21R pathway.
We used CD4
+ T cells obtained from IL-21 plasmid–treated
mice (injected with IL-21 pOrf plasmid) and from IL-21R
2/2
mice (with genetic deletion of the IL-21R gene) for in vitro
studies, conﬁrming the data obtained with the rmIL-21 and
mIL-21R.Fc (Supplementary Fig. 1A–D).
Signaling of IL-21/IL-21R prevents Treg generation
in vitro. We performed a Treg generation assay (20) to
investigate whether conversion from CD4
+CD25
2 cells (and,
thus, FoxP3
2)i n t oC D 4
+FoxP3
+ cells was affected by rmIL-21
or by the overexpression of IL-21 (through the use of hIL-21-
Tg mice or IL-21 plasmid–treated mice). In a complementary
experiment, we evaluated the effect of targeting IL-21 chem-
ically (mIL-21R.Fc) or genetically (IL-21R
2/2 mice) in the
same assays. We found a dose-dependent decrease in Treg
frequency when rmIL-21 was added compared with the per-
centage obtained without supplementation (no drug = 33.0 6
0.4%; 150 ng/mL rmIL-21 = 11.5 6 0.4%; P , 0.0001) (Fig. 2E
and F). An increase in Tregs was evident when mIL-21R.Fc
was added at high concentrations only (no drug = 33.0 6
0.4%; 150 ng/mL mIL-21R.Fc = 42.3 6 2.8%; P = 0.03) (Fig. 2E
and F). When CD4
+CD25
2 cells obtained from hIL-21-Tg or
IL-21 plasmid–treated mice were used, fewer Tregs were
generated as compared with when using CD4
+CD25
2 cells
from wild type (WT) and IL-21R
2/2 mice (Fig. 2G–L).
IL-21/IL-21R signaling inhibits Treg function and
induces Treg apoptosis in vitro. To explore whether
Tregs generated in the presence of IL-21 are dysfunctional
and unable to suppress Teff proliferation in vitro,
CD4
+CD25
2 5-(and 6)-carboxyﬂuorescein diacetate succi-
nimidyl ester (CFSE)-labeled T cells obtained from WT
C57BL/6.Thy1.2 mice were plated with the same number of
C57BL/6.Thy1.1 Tregs generated in the presence of high
concentrations (150 ng/mL) of rmIL-21 or mIL-21R.Fc or
with medium alone. After 72 h of stimulation, cells were har-
vested, and CFSE dilution was assessed on Thy1.1-negative
cells. It is interesting that an increased percentage of
Teff proliferation was evident when Tregs generated in the
presence of rmIL-21 were added compared with Tregs
generated in the absence of drugs or with mIL-21R.Fc (no
drug = 19.1 6 0.5%; rmIL-21 = 27.7 6 0.9%; mIL-21R.Fc =
16.1 6 0.3%; rmIL-21 vs. all, P , 0.05) (Fig. 3A and B). This
effect may be the result of both a reduced suppressive
ability of Tregs and increased Treg apoptosis. Control
CFSE-labeled CD4
+CD25
2 T cells stimulated in the absence
of Tregs were shown to undergo robust proliferation (Fig.
3A and B). To assess the mechanism through which IL-21
mediates a decrease in in vitro Treg generation, we per-
formed a Treg maintenance assay in which GFP
+ cells
(sorted by FoxP3-GFP mice) or CD4
+CD25
hi cells (obtained
through cell sorting of splenocytes extracted by IL-21
plasmid–treated or IL-21R
2/2 mice) were plated with anti-
CD3/CD28 monoclonal antibodies as well as IL-2 as a sur-
vival stimulus (17). A greater percentage of apoptotic Tregs
(AnnexinV
+/7-AAD
2) was observed in the presence of 150
ng/mL rmIL-21 compared with Tregs cultured in the absence
of any drug (no drug = 36.5 6 0.9%; rmIL-21 = 53.4 6 3.4%;
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expressing Tregs (from IL-21 plasmid–treated mice), but
not IL-21R
2/2 Tregs, displayed an increased apoptotic
rate in the maintenance assay (Fig. 3D). No differences in
mRNA levels of Bcl2, Bcl6, Bax, Caspase 3, Caspase 8,
cMyc, Fas, and FasL were detected in Tregs cultured in
the presence of rmIL-21 compared with control Tregs
(data not shown).
IL-21/IL-21R signaling inhibits FoxP3 transcription
without altering the FoxP3 methylation proﬁle in vitro.
To better understand the interplay of IL-21/IL-21R signaling
with Tregs, we performed RT-PCR studies to evaluate mRNA
transcript levels of FoxP3 and FoxP3-dependent genes in
Tregs cultured with 150 ng/mL rmIL-21 or mIL-21R.Fc (17).
RT-PCR expression studies conﬁrmed the reduction of FoxP3
mRNA levels (rmIL-21 = 0.2 6 0.0 fold decrease compared
FIG. 1. IL-21 is a cytokine of the late phase of the alloimmune response in vitro. The percentage of IL-21R
+ CD4
+ T cells (obtained from C57BL/6 mice)
after 1 day (D1) (A and B)a n d5d a y s( D 5 )( C and D) in an anti-CD3/CD28 stimulation assay in the presence of increasing concentrations of 5, 50, and
150 ng/mL rmIL-21 or mIL-21R.Fc or medium alone (no drug) (n = 3 experiments/conditions) was determined. IL-21R was highly expressed on CD4
+
T cells, without any considerable changes after day 1 (A and B). At day 5, the percentage of IL-21R
+CD4
+ T cells was reduced compared with baseline
in all conditions tested (baseline vs. all, #P < 0.05) (C and D). IL-21 levels in supernatants obtained in the anti-CD3/CD28 stimulation assay were
evaluated using the Luminex assay at different time points (n = 3 experiments/conditions). No detectable levels of IL-21 were found in supernatants
at day 1 after stimulation (E), whereas an increase was observed at day 5. High concentrations of mIL-21R.Fc (150 ng/mL) signiﬁcantly reduced IL-21
levels (no drug vs. 150 ng/mL mIL-21R.Fc, *P =0 . 0 1 )( F). The addition of serial concentrations of rmIL-21 induced an increase in IL-21 levels at days 1
and 5 (no drug vs. rmIL-21, *P < 0.05) (E). IFN-g–producing CD4
+ and CD8
+ T cells extracted from naïve C57BL/6 mice and cultured with anti-CD3/
CD28 in the presence of 5, 50, and 150 ng/mL rmIL-21 or mIL-21R.Fc or with medium alone (no drug) were evaluated using the ELISpot assay (G and
H)( n = 3 experiments/conditions). An increase in IFN-g–producing CD4
+ and CD8
+ T cells was evident on the addition of rmIL-21 (no drug vs. 50 and
150 ng/mL rmIL-21, *P < 0.05) (G and H). The frequencies of IFN-g–producing CD4
+ and CD8
+ T cells did not change when mIL-21R.Fc was added to
the anti-CD3/CD28 assay (no drug vs. 5, 50, and 150 ng/mL mIL-21R.Fc, NS) (G and H). IFN-g and IL-4 levels were evaluated in supernatants obtained
from anti-CD3/CD28 stimulation assays at day 5 using the Luminex assay (n = 3 experiments/conditions). Increased levels of IFN-g were detected in
the presence of rmIL-21 (no drug vs. 150 ng/mL rmIL-21, *P = 0.0008), whereas IFN-g levels were reduced in the presence of mIL-21R.Fc (no drug vs.
50 and 150 ng/mL mIL-21R.Fc, *P < 0.05) (I). A dose-dependent increase in IL-4 levels was observed in the presence of rmIL-21 (no drug vs. 5, 50, and
150 ng/mL rmIL-21, *P < 0.05), whereas no changes were evident in the presence of mIL-21R.Fc (no drug vs. 5, 50, and 150 ng/mL mIL-21R.Fc, NS) (J).
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(CTLA4, Nrp-1, and FasL) in the presence of rmIL-21 (Fig.
3F–H). mIL-21R.Fc did not induce any modiﬁcations in FoxP3
and FoxP3-targeted gene expression. To assess whether
IL-21 inhibition of TGF-b–driven differentiation of Tregs is
mediated by FoxP3 epigenetic reprogramming, we evalu-
ated the DNA methylation proﬁle, through pyrosequencing
(see Supplementary Data), of two regions of the FoxP3
gene (Intron 1 and Distal Promoter) known to be highly
and poorly methylated, respectively, at basal conditions
(16) in Tregs generated in the presence of rmIL-21 or mIL-
21R.Fc or without any supplementation (Fig. 3I). No dif-
ferences were evident in the CpG base pair percentage in
the Intron 1 region (mainly hypermethylated) or the Distal
Promoter region (mainly hypomethylated) regardless of
rmIL-21 or mIL-21R.Fc presence (Fig. 3I).
Further conﬁrmation of a non-FoxP3 methylation–
mediated mechanism of IL-21 action was sought by ex-
amining the ability of decitabine or 5-Aza-29-deoxycytidine
(a DNA hypomethylating agent), to promote Treg generation
in the presence of rmIL-21 (24). As previously shown (24),
treatment with decitabine alone was able to induce Treg
generation (D-percentage compared with no drug: no
drug = 100.0 6 17.7% vs. decitabine = 180.3 6 17.3%; P =
0.01) (Fig. 3J). Decitabine was, however, unable to increase
CD4
+FoxP3
+ cells in the presence of rmIL-21 (D-percentage
compared with no drug: rmIL-21 = 29 6 3.6% vs. rmIL-21 +
decitabine = 26 6 2.9%; NS) (Fig. 3J).
IL-21/IL-21R levels and expression during the alloimmune
response in vivo. We then evaluated the percentage
of IL-21R
+ T cells and B cells as well as levels of IL-21
during the alloimmune response in a murine model of islet
transplantation in vivo. Islets harvested from BALB/c mice
were transplanted under the kidney capsule of hypergly-
cemic C57BL/6 (STZ) mice and treated with mIL-21-R.Fc,
treated with control antibody (anti–E. tenella), or left un-
treated. No changes in CD4
+IL-21R
+,C D 8
+IL-21R
+,o r
B220
+IL-21R
+ cell percentage were evident in the spleen at
days 7 and 14 after transplantation (Fig. 4A–C). IL-21 se-
rum levels analyzed at the same time points as above were
not different at day 7 (Fig. 4D) but increased at day 14
after islet transplantation in the three groups of mice (Fig.
4D). The expression of the IL-21/IL-21R pathway was
further evaluated in the graft inﬁltrate of untreated and
mIL-21R.Fc–treated islet-transplanted mice at 7 and 14 days
after islet transplantation. We found that IL-21R mRNA
signiﬁcantly increased at day 14 compared with baseline
(in freshly isolated islets) and at day 7 (day 14 = 11.7 6 2.5
fold increase compared with baseline; baseline vs. day 14,
P = 0.04) (Fig. 4E) in untreated mice, while a lower but
not signiﬁcant intraislet expression of IL-21R mRNA was
evident 14 days after islet transplantation in mIL-21R.
Fc–treated compared with untreated mice (Fig. 4E).
Targeting IL-21/IL-21R expands intragraft Tregs and
promotes tolerance in vivo. We then tested the impact
of targeting the IL-21/IL-21R axis (using the mIL-21R.Fc
FIG. 2. IL-21/IL-21R signaling and overexpression inhibits Treg generation in vitro. A Treg generation assay was performed in vitro in the presence
of rmIL-21 or mIL-21R.Fc or medium alone (no drug) (n = 3 experiments/conditions). CD4
+CD25
2 cells extracted from C57BL/6 mice by magnetic
microbeads were cultured with anti-CD3/CD28 antibodies, TGF-b, and increasing concentrations of rmIL-21 or mIL-21R.Fc (both at 5, 50, and 150
ng/mL) or no drug (A and B). After 4 days of culture, the percentage of CD4
+FoxP3
+ cells was evaluated (Tregs). Although rmIL-21 supple-
mentation suppressed Treg generation (no drug vs. 50 and 150 ng/mL rmIL-21, *P < 0.0001), the addition of mIL-21R.Fc promoted Treg expansion
(no drug vs. 150 ng/mL mIL-21R.Fc, *P = 0.03) (n = 3 experiments/conditions) (A and B). Treg generation was performed with WT, hIL-21-Tg, IL-21
plasmid–treated, and extracted IL-21R
2/2 CD4
+CD25
2 T cells (n = 3 experiments/conditions) (C–H). A reduction of 70% compared with baseline
(WT mice) in Treg generation was evident when CD4
+ T cells were obtained from IL-21–overexpressing mice (WT vs. IL-21 plasmid treated and
hIL-21-Tg, *P < 0.0001) (C–F), whereas no differences were evident when using IL-21R
2/2 CD4
+CD25
2 (WT vs. IL-21R
2/2, NS) (G and H).
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status. A suppression assay was performed in which CFSE-labeled CD4
+CD25
2 cells were stimulated with anti-CD3/CD28 antibodies. Their pro-
liferation was then assessed in the presence of Tregs generated with high concentrations of rmIL-21 or mIL-21R.Fc (both at 150 ng/mL) or without
any drug supplementation (n = 3 experiments/conditions) (A and B). The proliferation of stimulated CD4
+CD25
2 in the absence of Tregs was also
evaluated (baseline vs. all, #P < 0.01) (A and B). Tregs generated in the presence of rmIL-21 displayed reduced suppression of CD4
+CD25
2 T-cell
proliferation compared with control (no drug vs. rmIL-21, *P = 0.01). On the contrary, mIL-21R.Fc–induced Tregs showed an increased ability to
suppress CD4
+CD25
2 T-cell proliferation compared with control (no drug vs. mIL-21R.Fc, *P = 0.04) (A and B). The apoptotic rate of FoxP3-GFP
+
cells (extracted from FoxP3-GFP-B6 mice) plated with anti-CD3/CD28 antibodies, IL-2, and high concentrations of rmIL-21 or mIL-21R.Fc (both at
150 ng/mL) or with no drug was evaluated in a Treg maintenance assay (n = 3 experiments/conditions) (C). FoxP3-GFP
+ cells cultured with rmIL-
21 displayed a higher percentage of AnnexinV
+/7-AAD
2 apoptotic cells compared with those cultured with no drug (no drug vs. rmIL-21, *P = 0.04)
(C). A greater percentage of apoptotic CD4
+CD25
hi cells was evident when cells were obtained from IL-21 plasmid–treated mice (WT vs. IL-21
plasmid treated, *P = 0.007) (D), whereas no differences in apoptotic rate were evident when cells were derived from IL-21R
2/2 mice (WT vs. IL-
21R
2/2, NS) (n = 3 experiments) (D). There were fewer FoxP3 mRNA transcripts in Tregs generated in the presence of rmIL-21 (n = 3 experi-
ments) (no drug vs. rmIL-21, *P = 0.01) (E). FoxP3-related gene expression (CTLA4 [no drug vs. rmIL-21,* P = 0.03]; Nrp-1 [no drug vs. rmIL-21,
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+ cell expansion and ulti-
mately on allograft survival and tolerance induction in
a model of the alloimmune response in vivo (i.e., islet
transplantation). Untreated C57BL/6 mice rapidly rejected
islet allografts (mean survival time [MST] of 14 days, n =5 ) ,
and treatment with the negative control antibody anti–E.
tenella led to similar graft survival (MST of 13 days, n =5 )
(Fig. 4F). mIL-21R.Fc treatment prolonged graft survival,
leading to long-term tolerance, deﬁned as MST .100 days,
in 20% of treated mice (MST: untreated = 14 days; anti–E.
tenella treated = 13 days; mIL-21R.Fc treated = 19 days;
mIL-21R.Fc treated vs. all, P , 0.05) (Fig. 4F). We there-
fore combined mIL-21R.Fc with CTLA4-Ig treatment
(CTLA4-Ig: 500 mg at day 0; 250 mg at days 2, 4, 6, 8, and
10), with the aim of suppressing early T-cell activation
(which is likely IL-21 independent) through CTLA4-Ig (25).
CTLA4-Ig synergized with mIL-21R.Fc to further increase
allograft survival compared with treatment with either
mIL-21R.Fc or CTLA4-Ig alone, resulting in tolerance
induction in 100% of mice (percentage of tolerant mice:
CTLA4-Ig + mIL-21R.Fc treated = 100%; CTLA4-Ig alone
treated = 55%; mIL-21R.Fc treated = 20%; CTLA4-Ig +
mIL-21R.Fc treated vs. all, P # 0.01) (Fig. 4F). Histol-
ogical sections of the grafts were analyzed at day 14 and
at day 100 (Fig. 4G1–J5). Mice treated with anti–E. tenella
at day 14 after transplantation displayed a similar severe
inﬁltration of the graft, primarily consisting of CD3
+ and
B220
+ cells (Fig. 4G1–3 and H1–3), with absent insulin
staining (Fig. 4G5 and H5) and very few islet-nested
FoxP3
+ cells (Fig. 4G4 and H4). Conversely, in the mIL-
21R.Fc–treated group at day 14, islet morphology was
still well preserved with several detectable insulin-
producing cells and a mild CD3
+ cell inﬁltrate, primarily
made up of islet-nested FoxP3
+ cells and very few B cells
(Fig. 4I1–5). Islet morphology in tolerant CTLA4-Ig + mIL-
21R.Fc–treated mice at 100 days after transplantation
showed no T cells or B cells inﬁltrating the graft and
a clear insulin staining (Fig. 4J1–5). An increase in the
FoxP3
+-to-CD3
+ cell ratio, quantiﬁed with Aperio Tech-
nology (Vista, CA) (19), was observed at day 14 in mIL-21R.
Fc–treated mice compared with both untreated mice and
mice treated with anti–E. tenella (Fig. 4K). We conﬁrmed
our mIL-21R.Fc data and recent data (13) by transplanting
BALB/c islets into chemically induced (STZ) hyperglycemic
IL-21R
2/2 mice, and a prolongation of islet graft survival
compared with WT control mice was indeed observed (MST:
WT = 14 days; IL-21R
2/2 = 17 days; P = 0.01; data not shown).
Targeting IL-21/IL-21R expands peripheral Tregs
and regulates the antidonor immune response in vivo.
A reduction in the percentage of peripheral CD4
+
CD44
hiCD62L
low Teffs was evident in mIL-21R.Fc–treated
mice at 14 days after transplant compared with mice
treated with anti–E. tenella (controls) and untreated mice
and CD8
+CD44
hiCD62L
low cells (Fig. 5A–C). The per-
centage of peripheral CD4
+CD25
+FoxP3
+ cells (Tregs) in-
creased in mIL-21R.Fc–treated mice compared with the
other two groups (Fig. 5D and F), and a higher Treg-to-
Teff ratio was evident in mIL-21R.Fc–treated mice as
well (Fig. 5E). Ex vivo rechallenge of splenocytes
harvested at day 14 from islet-transplanted mice with
donor alloantigen (i.e., BALB/c splenocytes) displayed
a profound regulation of the antidonor-speciﬁci m m u n e
response in mIL-21R.Fc–treated mice, as shown by the
reduction of IFN-g–producing cells in the ELISpot as-
say (BD Bioscience, San Jose, CA) compared with
mice treated with anti–E. tenella and untreated mice
(IFN-g–producing cells per 0.5 3 10
6: untreated =
125.0 6 11.3; anti–E. tenella treated = 163.8 6 30.6; mIL-
21R.Fc treated = 25.3 6 4.9; mIL-21R.Fc treated vs. all,
P # 0.01) (Fig. 5G). Of interest, 14 days after islet
transplantation, a reshaping of the peripheral cytokine
proﬁle was evident in mIL-21R.Fc–treated mice as well,
with an overall suppression of proinﬂammatory cyto-
kines, as shown by the reduction of peripheral serum
levels of IFN-g, IL-2, IL-6, and IL-15 (Fig. 5H)c o m p a r e d
with controls and untreated mice. IL-4, IL-10, and IL-17
peripheral levels remained unchanged in response to all
treatments (Fig. 5H).
Targeting IL-21/IL-21R promotes Treg neogenesis in
vivo. We next asked whether targeting the IL-21/IL-21R
axis would be capable of promoting Treg neogenesis in
vivo. Thus, we tested whether mIL-21R.Fc treatment could
promote the generation of FoxP3 Tregs after depletion of
CD25 using an anti–CD25-Ig injection (500 mga td a y26
and at day 21 before islet transplantation). Treatment with
anti–CD25-Ig completely depleted CD25
+ cells and FoxP3
+
cells (data not shown). Targeting of the IL-21/IL-21R
axis (with mIL-21R.Fc) during anti–CD25-Ig treatment
slightly prolonged islet graft survival compared with anti–
CD25-Ig treatment alone (MST: anti–CD25-Ig + mIL-21R.Fc
treated = 25; anti–CD25-Ig treated = 20 days; P =0 . 0 4 )
(Fig. 6A). Moreover, mIL-21R.Fc showed the ability to
newly generate splenic CD4
+FoxP3
+ cells (Fig. 6B). To
verify the robustness of the tolerance induced by mIL-21R.
Fc + CTLA4-Ig treatment, we recovered 1 3 10
7 splenocytes
from long-term tolerant mice at day 50 after islet trans-
plantation and adoptively transferred them into immuno-
deﬁcient C57BL/6-RAG mice that had been islet transplanted
the day before with BALB/c islets. Splenocytes from
rejecting islet-transplanted C57BL/6 mice were used as
controls. Of interest, 100% of C57BL/6-RAG mice that
were adoptively transferred with splenocytes obtained
from long-term tolerant mice did not reject BALB/c
islets compared with the control group, which promptly
rejected BALB/c islets (MST: long-term tolerant mice = 100
days; rejecting mice = 14 days; P , 0.0001) (Fig. 6C). To
evaluate whether mice were immunocompetent, we trans-
planted skin grafts from third-party DBA/1 J (H2
q) donors
into mIL-21R.Fc + CTLA4-Ig–treated long-term tolerant
mice and into the control group of rejecting mice. Both
groups of mice invariably rejected third-party skin grafts
at ;14 days after transplantation, thus conﬁrming that
mice treated with mIL-21R.Fc + CTLA4-Ig are immunocom-
petent (Fig. 6D). Finally, we tested mIL-21R.Fc + CTLA4-Ig
treatment in a stringent model of tolerance resistance
and in which BALB/c islets were transplanted into NOD
mice, conﬁrming a prolongation of graft survival in
mice treated with mIL-21R.Fc + CTLA4-Ig compared with
*P = 0.01]; and FasL [no drug vs. rmIL-21, *P = 0.02]) was reduced as well (n = 3 experiments) (F–H). To evaluate whether the IL-21 effect on
Tregs was mediated by FoxP3 DNA epigenetic reprogramming and hypermethylation, we studied the methylation status of Tregs generated in vitro
in the presence of rmIL-21 or mIL-21R.Fc (both used at 150 ng/mL), and a similar percentage of methylation in two FoxP3 DNA regions (Intron 1
and Distal Promoter) was found (no drug vs. rmIL-21 vs. mIL-21R.Fc, NS) (n = 3 experiments) (I). These data were conﬁrmed by adding
a hypomethylating agent (decitabine) to rmIL-21 in an in vitro Treg generation assay in which no recovery of FoxP3
+ cells was evident (NS), while
decitabine (DEC) alone was able to induce an increase in Tregs (WT vs. DEC, *P = 0.01) (n = 3 experiments) (J).
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(Fig. 6E).
IL-21/IL-21R signaling in doxycycline-inducible
ROSA-rtTA-IL-21-Tg mice expands Teffs and FoxP3
2
cells. To conﬁrm the paramount effect of IL-21 on FoxP3
and Treg function/survival in vivo, we generated the
doxycycline-inducible ROSA-rtTA-IL-21-Tg mouse (Doxa-
inducible IL-21-Tg). This transgenic C57BL/6 mouse
expresses mIL-21 cDNA in a tetracycline-responsive
element composed of the tet operator sequence under
the control of a tetracycline-controlled transcriptional
activator M2 promoter (Fig. 6F–H). We then trans-
planted BALB/c islets into the Doxa-inducible IL-21-Tg
mice, followed by daily doxycycline administration be-
ginning from day 0 until rejection. Doxycycline-treated
Doxa-inducible IL-21-Tg mice rejected the grafts with the
same timing of Doxa-inducible IL-21-Tg untreated mice
(MST: WT doxycycline treated = 14 days vs. Doxa-inducible
FIG. 4. IL-21 is a cytokine of the late phase of the alloimmune response in vivo, and IL-21/IL-21R targeting promotes tolerance during the in vivo
alloimmune response. The expression of IL-21R on T cells and B cells as well as IL-21 peripheral levels were analyzed in vivo during the alloimmune
response in chemically induced (STZ) diabetic islet-transplanted C57BL/6 mice. IL-21R was highly expressed on CD4
+, CD8
+, and B220
+ cells at
baseline, and no differences were evident at the time points tested (days 7 and 14) in all groups of mice studied (n = 4 mice/time point) (A–C).
Peripheral IL-21 levels were evaluated using the Luminex assay, which evaluated an increase in IL-21 levels at day 14 after transplant in untreated
mice (n = 4) and mice treated with anti–E. tenella (n = 4) and mIL-21R.Fc (n = 4) (albeit to a lower extent in the latter two groups) compared with
baseline (baseline vs. all, *P < 0.05) (D). An increase in IL-21R mRNA expression in islet grafts was evident at day 14 in untreated islet-transplanted
mice compared with baseline (in freshly isolated islets) (baseline vs. day 14, *P = 0.04) (n =3 )( E), while lower expression was evident in mice
treated with mIL-21R.Fc (E). Untreated C57BL/6 mice rapidly rejected islets (MST of 14 days, n = 8) and treatment with anti–E. tenella led to
a similar graft survival (MST of 13 days, n =5 )( F). mIL-21R.Fc treatment (n = 5) prolonged graft survival, leading to 20% tolerance (MST >100
days) to islet grafts (MST: untreated = 14 days; anti–E. tenella treated = 13 days; mIL-21R.Fc treated = 19 days; mIL-21R.Fc treated vs. all, *P <
0.05) (F). Treatment with CTLA4-Ig (500 mg at day 0; 250 mg at days 2, 4, 6, 8, and 10) synergized with mIL-21R.Fc treatment (n = 9) to further
increase allograft survival compared with either mIL-21R.Fc or with CTLA4-Ig alone treatment, resulting in tolerance in 100% of mice (percentage
of tolerance: CTLA4-Ig + mIL-21R.Fc treated = 100%; CTLA4-Ig treated = 55%; mIL-21R.Fc treated = 20%; CTLA4-Ig + mIL-21R.Fc vs. CTLA4-Ig
treated [*P = 0.01] and vs. mIL-21R.Fc treated [*P = 0.001]) (F). Histological sections of the graft at day 14 and at day 100 after transplantation
(G1–J5) revealed that untreated mice and mice treated with anti–E. tenella at day 14 displayed a complete loss of islet architecture and severe
CD3
+/B220
+ cell inﬁltration of the graft, with few nested FoxP3
+ cells and absent insulin staining (n =3 )( G1–H5). mIL-21R.Fc–treated mice
presented preserved islet morphology with mild CD3
+/B220
+ cell inﬁltration, primarily constituted of FoxP3
+ cells, as well as clearly detectable
insulin staining (n =3 )( I1–5). CTLA4-Ig + mIL-21R.Fc–treated tolerant mice at day 100 (n = 3) displayed well-preserved islet architecture with no
CD3
+/B220
+ cell inﬁltration in the graft and clear insulin staining (J1–5). H&E, hematoxylin-eosin. FoxP3
+ and CD3
+ cells inﬁltrating the graft at
day 14 were evaluated using Aperio Technology. Greater FoxP3
+-to-CD3
+ cell ratio was evident in mIL-21R.Fc–treated mice compared with both
control groups (mIL-21R.Fc treated vs. untreated and anti–E. tenella treated, *P = 0.04, n = 3 mice per group) (K). D, day. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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inducible IL-21-Tg mice treated with doxycycline showed
similar percentage of CD4
+CD25
+FoxP3
+ cells (data not
shown), with a clear expansion of CD4
+CD44
hiCD62L
low
cells (Fig. 6I), CD8
+CD44
hiCD62L
low cells (Fig. 6J), and
CD4
+CD25
+FoxP3
2 cells (Doxa-inducible IL-21-Tg un-
treated = 9.7 6 1.2%; Doxa-inducible IL-21-Tg doxycycline
treated = 30.8 6 5.0%; P = 0.002) (Fig. 6K).
FIG. 5. IL-21/IL-21R targeting expands peripheral Tregs in vivo and regulates the alloimmune response. The effect of targeting IL-21 in the
alloimmune response was analyzed in vivo in islet-transplanted mice during the pathogenesis of the alloimmune response. Splenocytes at day 14
after islet transplantation were harvested from untreated mice (n = 4) and mice treated with anti–E. tenella (n = 4) and mIL-21R.Fc (n = 4) and
were analyzed by ﬂuorescence-activated cell sorter. The percentages of CD4
+ and CD8
+ Teffs (CD4
+CD44
hiCD62L
lo and CD8
+CD44
hiCD62L
lo cells)
were lower in the mIL-21R.Fc–treated group compared with untreated mice and mice treated with anti–E. tenella (mIL-21R.Fc treated vs. un-
treated and anti–E. tenella treated, *P < 0.05) (A–C). The percentage of Tregs was greater in the mIL-21R.Fc–treated mice compared with un-
treated mice and mice treated with anti–E. tenella (mIL-21R.Fc treated vs. untreated and anti–E. tenella treated, *P < 0.05) (D and F), as was the
Treg-to-Teff ratio (mIL-21R.Fc treated vs. untreated and anti–E. tenella treated, *P < 0.05) (E). The percentage of IFN-g–producing cells was
evaluated in an ex vivo antidonor immune response using an ELISpot assay. Splenocytes harvested at day 14 after transplant were rechallenged ex
vivo with irradiated BALB/c splenocytes, and the number of IFN-g–producing cells was evaluated. mIL-21R.Fc–treated mice (n = 3) showed a re-
duced number of IFN-g–producing cells compared with untreated mice (n = 3) and mice treated with anti–E. tenella (n = 3) (mIL-21R.Fc treated vs.
untreated and anti–E. tenella treated, *P < 0.05) (G). The peripheral cytokine proﬁle was studied in serum samples of the three groups of mice at
day 14 after transplantation, which revealed an overall suppression of proinﬂammatory cytokines (IFN-g, IL-2, IL-6, and IL-15) in the mIL-21R.Fc–
treated group (mIL-21R.Fc treated [n = 3] vs. untreated [n = 3] and anti–E. tenella treated [n = 3], *P < 0.05) (H).
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+CD25
+Fox3
+-to-CD4
+CD25
+FoxP3
2 cell ra-
tio is reduced in Doxa-treated mice compared with controls
(Fig. 6L). The absence of CD4
+CD25
+FoxP3
+ cell reduction
in Doxa-inducible IL-21-Tg mice observed in the acute
model may be related to the fast tempo of acute rejection,
which may not ﬁt with the IL-21 role. To further clarify this
FIG. 6. IL-21/IL-21R targeting generates new Tregs, and IL-21 inducible overexpression expands FoxP3
2 cells in vivo. To assess whether IL-21
targeting promotes the neogenesis of FoxP3 Tregs, we pretreated C57BL/6 mice with a CD25-depleting agent (i.e., anti–CD25-Ig capable of depleting
CD4
+CD25
+ cells) the day before mice received islets from BALB/c donors. Mice were then treated with mIL-21R.Fc or were left untreated. Mice
treated with mIL-21R.Fc displayed slight prolongation in graft survival (MST: anti–CD25-Ig treated = 20 days vs. anti–CD25-Ig + mIL21-R.Fc treated =
25 days, *P =0 . 0 3 )( A) but signiﬁcant neogeneration of CD4
+FoxP3
+ cells (*P = 0.005) at the day of rejection compared with untreated mice (B). To
test the robustness of tolerance toward alloantigen, long-term tolerant splenocytes harvested from mice treated with CTLA4-Ig + mIL-21R.Fc or from
rejecting mice as controls were adoptively transferred (AT) into immunodeﬁcient C57BL/6 RAG mice 1 day after BALB/c islet transplantation (C). Of
mice receiving splenocytes from long-term tolerant mice, 100% did not reject islet grafts, whereas all mice injected with splenocytes harvested from
rejecting mice rejected islet graft with a pattern similar to naïve untreated C57BL/6 mice (MST: tolerant splenocytes = 100 days vs. rejected sple-
nocytes = 14 days, *P < 0.0001) (C). To test immunocompetence of long-term tolerant mice, skin grafts from third-party donors (DBA/1 J [H2
q]) were
transplanted into mice treated with mIL-21R.Fc + CTLA4-Ig or control rejecting mice (D). All mice rejected donor-derived skin grafts with the same
timing, conﬁrming that mice treated with CTLA4-Ig + mIL-21R.Fc are immunocompetent (D). To further test the efﬁcacy of mIL-21R.Fc + CTLA4-Ig
treatment, we performed islet transplantation in a stringent model of tolerance resistance. BALB/c islets were transplanted into spontaneously
hyperglycemic NOD mice and treated with CTLA4-Ig + mIL-21R.Fc, CTLA4-Ig alone, or were left untreated. Mice treated with CTLA4-Ig + mIL-21R.Fc
showed a signiﬁcant prolongation of graft survival compared with both CTLA4-Ig–treated (*P = 0.01) and untreated mice (*P =0 . 0 0 8 )( E). A
transgenic C57BL/6 doxycycline-inducible IL-21-Tg mouse was generated, allowing IL-21 to be induced when needed (F–H). The murine IL-21 cDNA
was subcloned into the Sal I and Xba I sites of the pTRE-Tight vector (F). The Xho I restriction fragment, encompassing the Ptight tet-responsive
promoter, the IL-21 cDNA, and the SV40 poly A sequence, was excised and used to generate IL-21-Tg founder mice on a C57BL/6 background. The
location and relative size of the PCR products used to identify the Tg mice are indicated (G). The IL-21-Tg mice were crossed with ROSA rtTA*M2
transgenic mice to introduce the Doxa-regulated reverse transcriptional activator. The resulting progeny were screened by PCR to identify the IL-21-
Tg
+ mice used in this study (H). Doxycycline-inducible IL-21-Tg mice (on a C57BL/6 background) were transplanted with BALB/c islets and ad-
ministered doxycycline at day 0 to induce IL-21. At the time of rejection, doxycycline-induced mice (n = 5) showed an increased percentage of
CD4
+CD44
hiCD62L
low cells (*P =0 . 0 0 0 9 )( I), CD8
+CD44
hiCD62L
low cells (*P =0 . 0 0 1 )( J), and CD4
+CD25
+FoxP3
2 cells (*P =0 . 0 0 2 )( K), and
a reduced CD25
+FoxP3
+-to-CD25
+FoxP3
2 cell ratio (*P =0 . 0 0 0 1 )( L) in the spleen compared with control mice (n =4 ) .
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islet-transplanted mice with CTLA4-Ig + mIL-21R.Fc, and we
have then induced IL-21 by doxycycline administration 40
days after transplantation. Very few Tregs (3.7 6 0.5%) were
detected in mice 20 days after doxycycline administration,
when mice started to be sick.
DISCUSSION
FoxP3
+ Tregs play an essential role in maintaining immu-
nological unresponsiveness to alloantigens and in sup-
pressing the immune response (26). Herein, we propose IL-21
as an anti-FoxP3/anti-Treg cytokine of the late-phase
alloimmune response that disrupts FoxP3 and alters Treg
function, thereby acting as an antitolerogenic factor, thus
eliciting an enhanced alloimmune response, and creating
a barrier to transplant tolerance (1). In our study, IL-21
was increased in vitro after 5 days in anti-CD3/CD28 and
MLR assays and in vivo 14 days after islet transplantation.
IL-21R expression decreased in vitro after 5 days of stim-
ulation and was found elevated in the graft inﬁltrate of
rejecting untreated mice at later time points as well. Fur-
thermore, mIL-21R.Fc (a fusion protein that prevents the
binding of murine IL-21 to IL-21R) (22) is effective in vitro
only in the late phase of allostimulation. These data,
combined with the head-to-head comparison of IL-2 and
IL-21 levels in vitro and in vivo (Fig. 7), revealed that in
a “physiological” alloimmune setting, IL-21 is not responsible
for the early response to alloantigen (unlike IL-2), but it does
exert its function in the late-phase immune response (Fig. 7)
(27). It is possible that IL-21 ensures the redundancy of
the system, thus maintaining activation of the alloimmune
Early-phase Early-phase Late-phase Late-phase
FIG. 7. IL-21 acts as an antitolerogenic cytokine of the late phase of alloimmune response. In the early phase of the alloimmune response, antigen-
presenting cells activate T cells through two signals. Proinﬂammatory cytokines (i.e., IL-2) are locally released, leading to alloreactive T-cell
proliferation and destruction of the graft (D0 vs. all, *P < 0.01). In the late phase of the alloimmune response, Teffs release IL-21, thus ablating
FoxP3
+ Tregs, reducing FoxP3 gene transcripts, decreasing Treg generation and Treg suppressive properties, increasing Treg apoptosis, and in-
ducing Teff expansion (D5 and D14 vs. all, *P < 0.01). D, day. DC, dendritic cells. (A high-quality color representation of this ﬁgure is available in
the online issue.)
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21 is capable of enhancing the alloimmune response, as
shown by our in vitro experiments with rmIL-21 and with IL-
21 plasmid–treated or hIL-21-Tg mice. However, it is likely
that IL-21 may have a different role in the physiological
alloimmune setting as a mediator of FoxP3 and of Treg
dysfunction. The IL-21 interplay with Tregs was tested
in vitro, using assays for Treg generation, survival, and
function, during the challenge with rmIL-21 or mIL-21R.Fc,
or by using hIL-21-Tg, IL-21 plasmid–treated (which
overexpress IL-21), or IL-21R
2/2 mice. We show that TGF-
b–driven conversion of CD4
+CD25
2 T cells (FoxP3
2),
Treg survival, and Treg suppressive function are negatively
affected by rmIL-21 but positively affected by mIL-21R.Fc.
Indeed, we demonstrate an inhibition of FoxP3 and FoxP3-
dependent gene transcripts by IL-21 (28), without evidence
of IL-21–mediated epigenetic reprogramming of the FoxP3
gene, at least at the methylation level. These data were
further conﬁrmed by the inability of the demethylating
agent decitabine to rescue Tregs in the presence of rmIL-21,
thus indicating that despite the fact that decitabine is a ro-
bust inducer of Tregs in vitro (29), IL-21 is more potent in
inhibiting Treg generation. We therefore demonstrate that
blockade of the IL-21/IL-21R axis (both chemically and ge-
netically) during the alloimmune response in vivo promotes
the expansion of intragraft and peripheral Tregs and indu-
ces tolerance when combined with CTLA4-Ig, which targets
early T-cell activation and is likely IL-21 independent. We
show that mIL-21R.Fc promotes FoxP3 Treg neogenesis in
vivo and that the mechanism of tolerance induction is ro-
bust and transferable to nude mice. The strong effect of the
combination of mIL-21R.Fc and CTLA4-Ig on alloimmunity
does not apply to NOD mice, which show the coexistence
of strong allo- and autoimmune anti-islet responses (30).
Autoimmune response is mediated by several different
cell types (e.g., B cells, NK cells, macrophages, and Th17
cells), which may not be targeted by mIL-21R.Fc, but this
aspect will be further investigated. Finally, we provide
evidence that IL-21 promotes in vivo FoxP3
2 cell ex-
pansion. In fact, in our islet-transplanted Doxa-inducible
ROSA-rtTA-IL-21-Tg mice (31,32), in which IL-21 is in-
duced by doxycycline administration, both CD4
+ and CD8
+
activated/effector cells were found increased compared
with controls, while CD25
+FoxP3
+-to-CD25
+FoxP3
2 cell
ratio was reduced. Furthermore, long-term tolerant
mice overexpressing IL-21 (by doxycycline administra-
tion) showed very few Tregs. Taken together, our data
suggest that IL-21 is a potent inhibitor of the FoxP3 Treg
chain and an inducer of Teffs and that the blockade of
the IL-21/IL-21R pathway may induce a more tolero-
genic environment.
We posit that IL-21, together with other recently identiﬁed
cytokines (33–35), is part of a network of antitolerogenic
cytokines that through induction of Treg apoptosis or dys-
function, could represent a barrier to allograft tolerance. We
thus posit that blockade of the IL-21/IL-21R pathway should
be a precondition for many tolerogenic protocols in trans-
plantation. Our strategy may be relevant in controlling acute
as well as chronic rejection, which causes delayed islet
graft loss (36–38) and represents a barrier for long-term
allograft survival (39,40), since it abrogates T-cell acti-
vation in the early phase of posttransplant alloimmune
response (with CTLA4-Ig) and expands/induces Tregs in
the late phase (with IL-21 antagonist). We thus propose to
start both drugs at the day of transplantation, discontinuing
CTLA4-Ig treatment later on and prolonging the adminis-
tration of IL-21 antagonist.
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